

# BTX State of the Art unteres Gesichtsdrittel und Hals: Was macht Sinn? Wo sind Grenzen?

Autoren\_Dr. med. S. Hilton, A. Mocosch

## Literatur

- [1] Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev. 2005; CD004900
- [2] Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol. 2002; 59: 418-420
- [3] Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord. 2002; 17: 1288-1293
- [4] Karp BI, Cole RA, Cohen LG, Grill S, Lou JS, Hallett M. Long-term botulinum toxin treatment of focal hand dystonia. Neurology. 1994; 44: 70-76
- [5] Carruthers A, Carruthers J. The treatment of glabellar furrows with botulinum A exotoxin. J Dermatol Surg Oncol. 1990; 16: 83.
- [6] Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002; 46: 840-849.
- [7] Carruthers J, Carruthers A: long-term safety review of subjects treated with botulinum toxin type A for cosmetic use. Presentation EADV. 13<sup>th</sup> Congress, 17.-21. Nov. 2004a; Florenz.
- [8] Ascher B, Talarico S, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood unit) – part II: Wrinkles on the middle and lower face, neck and chest. JEADV 2010; 24: 1285-1295.